- Home
- KBR vs ITCI Comparison
KBR vs ITCI Comparison
Compare KBR & ITCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KBR
- ITCI
- Stock Information
- Founded
- KBR 1901
- ITCI 2002
- Country
- KBR United States
- ITCI United States
- Employees
- KBR N/A
- ITCI N/A
- Industry
- KBR Military/Government/Technical
- ITCI Biotechnology: Pharmaceutical Preparations
- Sector
- KBR Industrials
- ITCI Health Care
- Exchange
- KBR Nasdaq
- ITCI Nasdaq
- Market Cap
- KBR 7.6B
- ITCI 8.7B
- IPO Year
- KBR 2006
- ITCI N/A
- Fundamental
- Price
- KBR $59.08
- ITCI $126.89
- Analyst Decision
- KBR Strong Buy
- ITCI Buy
- Analyst Count
- KBR 8
- ITCI 13
- Target Price
- KBR $79.00
- ITCI $100.31
- AVG Volume (30 Days)
- KBR 1.4M
- ITCI 2.9M
- Earning Date
- KBR 02-24-2025
- ITCI 02-20-2025
- Dividend Yield
- KBR 1.02%
- ITCI N/A
- EPS Growth
- KBR N/A
- ITCI N/A
- EPS
- KBR 2.39
- ITCI N/A
- Revenue
- KBR $7,350,000,000.00
- ITCI $613,728,000.00
- Revenue This Year
- KBR $10.75
- ITCI $48.41
- Revenue Next Year
- KBR $17.11
- ITCI $38.26
- P/E Ratio
- KBR $24.76
- ITCI N/A
- Revenue Growth
- KBR 7.55
- ITCI 46.08
- 52 Week Low
- KBR $51.60
- ITCI $62.78
- 52 Week High
- KBR $72.60
- ITCI $128.00
- Technical
- Relative Strength Index (RSI)
- KBR 51.37
- ITCI 87.18
- Support Level
- KBR $55.92
- ITCI $80.83
- Resistance Level
- KBR $59.72
- ITCI $128.00
- Average True Range (ATR)
- KBR 1.40
- ITCI 2.57
- MACD
- KBR 0.42
- ITCI 4.45
- Stochastic Oscillator
- KBR 83.16
- ITCI 97.65
About KBR KBR Inc.
KBR, formerly Kellogg Brown & Root, is global provider of technology, integrated engineering, procurement, and construction delivery, and operations and maintenance services. The company's business is organized into two segments: government solutions and sustainable technology solutions. KBR has operations in over 30 countries and employs approximately 34,000 people. The firm generated $7 billion in revenue in 2023.
About ITCI Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.